<DOC>
	<DOC>NCT02138552</DOC>
	<brief_summary>The objective of this clinical trial is to identify the most efficacious octenidine dihydrochloride concentration regarding bacterial count reduction in comparison to a placebo in the oral cavity.</brief_summary>
	<brief_title>Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo</brief_title>
	<detailed_description />
	<mesh_term>Gingivitis</mesh_term>
	<mesh_term>Octenidine</mesh_term>
	<criteria>Patients with mild gingivitis (mean GI: 0.2 1.0) Patients with complete natural "Ramfjordteeth" or their replacement teeth Caucasian Signed Informed Consent Patients with severe systemic diseases (diabetes, hepatitis, HIV, tuberculosis, cancer) Patients who require endocarditis prophylaxis for dental examination and treatment Caries requiring treatment (e.g. caries with cavity) or other oral diseases (incl. gingival hyperplasia, diseases of the oral mucosa, periodontal screening index PSI &gt; 2) Patients with orthodontic appliances and removable dentures Patients treated with antibiotics less than 3 months prior to the baseline examination at V1 and/or such a treatment planned for the duration of the trial Patients chronically treated with steroids Patients who suffer from xerostomia Patients who regularly smoke more than 10 cigarettes per day Patients who have a known hypersensitivity or allergy to the test product and its ingredients or to medications that have a similar chemical structure Participation of the patient in another clinical trial within the last four weeks before enrollment in this trial Incapability of assessing essence and possible consequences of the trial (e.g. alcoholism) Pregnant or breastfeeding women Women with childbearing potential except those who fulfill the following criteria: Postmenopausal (12 month of natural amenorrhoea or 6 months of amenorrhoea with Serum FSH &gt; 40 U/ml) Postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy) Continuous and correct application of a contraception method with a Pearl Index &lt; 1% (e.g. implants, depots, oral contraceptives, intrauterine device IUD)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>